Pharmaceutical and biotech companies have a regulatory obligation to prepare plans for and conduct studies in paediatric patient populations in both EU countries and the US. Colin Hayward at Premier Research highlights differences and similarities in the paediatric regulatory compliance strategies and priorities of companies in those regions.